SCHEMBL20876239

SCHEMBL20876239

CCC1(c2ccccc2)COc2c(Br)cc(C(=O)O)cc21

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 9/20 0.51
PTGS1 P23219 4/20 0.36
PTGS2 P35354 4/20 0.36
ALOX5 P09917 2/20 0.36
F11 P03951 1/20 0.35
TTR P02766 1/20 0.33
BRD2 P25440 1/20 0.33
BRD3 Q15059 1/20 0.33
BRDT Q58F21 1/20 0.33
HCAR3 P49019 1/20 0.33
HCAR2 Q8TDS4 1/20 0.33
KDM4E B2RXH2 2/20 0.32
GAA P10253 2/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
RXRA P19793 1/20 0.32
NPSR1 Q6W5P4 2/20 0.31
ALDH1A1 P00352 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20876267 0.89 BRD4 (0.50) BRD4PTGS1PTGS2ALOX5TTR
SCHEMBL20887580 0.89 BRD4 (0.50) BRD4PTGS1PTGS2ALOX5KDM4E
SCHEMBL29596450 0.89 BRD4 (0.50) BRD4PTGS1PTGS2ALOX5KDM4E
SCHEMBL20887624 0.81 BRD4 (0.74) BRD4F11BRD2BRD3BRDT
SCHEMBL29596457 0.81 BRD4 (0.74) BRD4F11BRD2BRD3BRDT
SCHEMBL20876232 0.81 BRD4 (0.74) BRD4F11BRD2BRD3BRDT
SCHEMBL20876233 0.81 BRD4 (0.58) BRD4PTGS1PTGS2ALOX5TTR
SCHEMBL20887712 0.79 BRD4 (0.51) BRD4PTGS1PTGS2ALOX5KDM4E
SCHEMBL29596396 0.79 BRD4 (0.51) BRD4PTGS1PTGS2ALOX5KDM4E
SCHEMBL20876234 0.79 BRD4 (0.48) BRD4PTGS1PTGS2ALOX5F11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319307-B2 2,3-dihydrobenzohurans as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2022-05-03 US disclosed
US-20200291009-A1 2,3-DIHYDROBENZOFURANS AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2020-09-17 US disclosed
EP-3692036-A1 2,3-DIHYDROBENZOFURANS AS BOROMODOMAIN INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2020-08-12 EP disclosed
WO-2019068782-A1 2,3-DIHYDROBENZOFURANS AS BOROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2019-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200291009-A1 2,3-DIHYDROBENZOFURANS AS BROMODOMAIN INHIBITORS BRD4, BRPF3, BRD3 BRD4 1/4885PTGS1 1509/4885PTGS2 1519/4885
US-11319307-B2 2,3-dihydrobenzohurans as bromodomain inhibitors BRD4, BRD3, BRPF3 BRD4 1/4885PTGS1 1109/4885PTGS2 1144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.